2013
Prescription of Second-Generation Antipsychotics: Responding to Treatment Risk in Real-World Practice
Hermes ED, Sernyak MJ, Rosenheck RA. Prescription of Second-Generation Antipsychotics: Responding to Treatment Risk in Real-World Practice. Psychiatric Services 2013, 64: 238-244. PMID: 23241613, DOI: 10.1176/appi.ps.201200183.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsProportion of patientsCardiometabolic riskCardiometabolic disordersCardiovascular diseaseSociodemographic dataSingle Veterans Affairs medical centerVeterans Affairs Medical CenterChoice of antipsychoticHigh cardiometabolic riskPatients' sociodemographic dataQuality of careAntipsychotic prescribedReal-world practicePsychiatric providersTreatment decisionsMedical CenterTreatment risksComorbid diagnosesPatientsAntipsychoticsSignificant associationModerate riskNew prescriptionsProvider sensitivity
2012
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The Journal Of Clinical Psychiatry 2012, 73: 526-32. PMID: 22579152, PMCID: PMC3786588, DOI: 10.4088/jcp.11m07162.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScalePANSS scoresClinical Antipsychotic TrialsImportant difference estimatesNegative Syndrome ScaleAntipsychotic TrialsSyndrome ScaleLong-term effectiveness trialsIntervention Effectiveness (CATIE) schizophrenia trialShort-term efficacy trialsGlobal Impression ScaleBaseline PANSS scoresLower baseline scoresClinical workIllness scoresMulticenter trialCGI scoresCGI severityImpression ScaleSchizophrenia trialsEffectiveness trialPatient ratingsEfficacy trialsImportant differencesBaseline scores